頁籤選單縮合
題 名 | 從路易氏體失智症之病理特徵找尋治療方法=Exploring a Therapeutic Method for Dementia with Lewy Bodies Based on the Pathophysiology |
---|---|
作 者 | 何應瑞; 許弘毅; 張鳴宏; 廖玟潔; 林志立; 洪菁穗; | 書刊名 | 臺灣醫學 |
卷 期 | 23:3 2019.05[民108.05] |
頁 次 | 頁376-383 |
分類號 | 415.8471 |
關鍵詞 | 神經退化性疾病; 路易氏體失智症; 頭孢曲松; 麩胺酸; Neurodegenerative disorders; Dementia with Lewy bodies; Ceftriaxone; Glutamate; |
語 文 | 中文(Chinese) |
中文摘要 | 路易氏體失智症(dementia with Lewy bodies, DLB)是許多神經退化性疾病中的一種,雖然這些疾病的症狀各異,但是具有如下的共同病理特徵:(1)α-突觸核蛋白(α-synuclein; α-syn)與β-amyloid(Aβ)交互作用生成路易氏體堆積,(2)麩胺酸(glutamate)過多引發神經毒性。頭孢曲松(ceftriaxone, CEF)過去長期作為抗生素治療感染性疾病之用,具有相當高的安全性。近年許多研究證實CEF具有下列功能:(1)可以與α-syn穩定結合,抑制其形成聚合物堆積;(2)啟動調節Aβ新陳代謝之相關基因,一方面抑制生成之基因,同時活化其分解之基因;(3)增加麩胺酸轉運蛋白(glutamate transporter-1, GLI-1)之表現,清除麩胺酸,降低興奮性毒性;(4)促進神經新生(neurogenesis),修復神經密度。上述效果均顯示CEF有利於治療神經退化性疾病,因此值得推動使用CEF治療DLB之臨床試驗,以驗證CEF在此疾病之效果。 |
英文摘要 | Dementia with Lewy bodies (DLB) is one of the neurodegenerative disorders that have different symptoms but some common pathophysiological features, for example: (1) deposition of Lewy bodies produced by interactions of α-synuclein (α-syn) and β-amyloid (Aβ); (2) glutamate-induced excitotoxicity. Ceftriaxone (CEF) is an old and safe drug being used as antibiotic. Recent studies have demonstrated the following effects of CEF: (1) binding well with α-syn and inhibing of α-syn polymerization; (2) modulation of genes related to Aβ metabolism, suppressing synthesis but increasing degradation; (3) increasing glutamate transporter-1 and glutamate reuptake, but decreasing excitotoxicity; (4) enhancing neurogenesis and recovery of neuronal density These results suggest a potential of CEF in treating neurodegenerative disorders. Thus, it is worthy to conduct a clinical trial to evaluate effects of CEF in DLB. |
本系統中英文摘要資訊取自各篇刊載內容。